Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

NCT00048308 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3000

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardio-pulmonary Bypass
Coronary Artery Bypass Graft

Interventions

DRUG: pexelizumab

Sponsor

Alexion Pharmaceuticals, Inc.